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Abstract
Background: The aim of the authors was to reassess the impact of a positive surgical margin (R1) after
a liver resection for colorectal liver metastases (CLMs) on survival in the era of modern chemotherapy,
through their own experience and a literature review.
Methods: Inclusion criteria were: R1 or R0 resection with no local treatment modalities, extra-hepatic
metastases or other cancer.
Results: Among 337 patients operated between 2000 and 2010, 273 patients were eligible (214 R0/59
R1). The mean follow-up was 43 ± 29 months. Compared with a R0 resection, a R1 resection offered a
lower 5-year overall (39.1% versus 54.2%, P = 0.010), disease-free (15.2% versus 31.1%, P = 0.021) and
progression-free (i.e. time to the first non-curable recurrence; 33.1% versus 47.3%, P = 0.033) survival
rates. Metastases in the R1 group were more numerous, larger and more frequently synchronous.
Independent factors of poor survival were: number, size and short-time interval of CLM occurrence, N
status, rectal primary, absence of adjuvant chemotherapy, but not a R1 resection. With the more-
systematic administration of chemotherapy since 2005, the intergroup difference in progression-free
survival disappeared (P = 0.264).
Conclusion: A R1 resection had no prognostic value per se but reflected a more severe disease. The
recent change in the prognostic value of a R1 resection may be linked to the beneficial effect of
chemotherapy.
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Introduction
Recent advances in chemotherapy and surgical techniques have
enabled surgeons to extend the indication for resection of
colorectal liver metastases (CLM). Multiple, massive and unfa-
vourably located CLMs can now be resected, leading to complex
hepatic resections that are more likely to incur a R1 resection.
Historically, microscopically incomplete R1 resections have been
associated with an elevated risk of recurrence at the surgical
margin1,2 and significantly lower survival rates.3,4 Until the 1990s,
a 10-mm margin was advocated because of the existence of
micrometastases up to 10 mm around the tumour.5 Nevertheless,
at that time, patients did not receive peri-operative chemotherapy.
In the early 2000s, Elias et al.6 showed that the prognosis did not
depend on the margin width (as long as the margin was negative).
In 2003, the French guidelines for clinical practice recommended
a 5-mm margin instead of a 10-mm margin.7 In 2008, de Haas
et al. showed no difference in overall survival (OS) between R0
and R1 patients and defined the R1 ‘by necessity’ conditioning the
resectability.8 In contrast, Dhir et al.’s9 2011 meta-analysis showed
that a 10-mm negative margin was associated with better survival
than a 1- to 10-mm negative margin was. Another recent study
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showed that patients with positive resection margins did not
survive for more than 10 years.10 There are several possible expla-
nations for these discrepancies: (i) distant recurrences as well as
margin recurrences both impact survival, (ii) a repeat hepatec-
tomy or local treatment of a margin recurrence counterbalances
the poor prognosis of a R1 resection and (iii) variations in the
inclusion period and inconsistent consideration of whether peri-
operative chemotherapy had been administered precluded an
analysis of the impact of continuous improvements in chemo-
therapy over time.
The aim of the present study was to analyse a population of
patients operated on in the authors’ university medical centre in
the 2000s, focusing on a period of more systematic administration
of chemotherapy (2005–2010), and to determine the influence of




An analysis of the authors’ prospectively-completed computerized
database established that 337 patients had been operated on for
CLMs in the authors’ institution between 2000 and 2010. Patients
were eligible for the study if they met the following criteria: a
complete macroscopic resection with clearly described surgical
margins in a histopathological examination, no evidence of con-
comitant extrahepatic disease, no simultaneous use of local treat-
ments (e.g. radiofrequency ablation) and no history of other types
of cancer. In patients who received peri-operative chemotherapy,
5-fluorouracil was administered with leucovorin, oxaliplatin or
irinotecan. Pre-operative chemotherapy was administered when
liver metastases were initially unresectable (i.e. inability to leave an
adequate remnant liver volume after complete removal of all
CLMs) or in a neoadjuvant setting in patients with synchronous
CLMs (CLMs having appeared within the previous 6 months) or
marginally resectable CLMs (≥5 bilateral nodules).8 As a rule,
most hepatic resections were performed 1 month after the end of
chemotherapy.11 Only chemotherapy administered within the 3
months preceding surgery was considered as neoadjuvant chemo-
therapy. With a few exceptions, only patients with down-sized or
stable disease after chemotherapy were candidates for a liver resec-
tion. Given that the number of patients having undergone chemo-
therapy was significantly greater in recent years, the authors also
compared two time periods, before and after 2005, also the year in
which targeted therapies such as bevacizumab and cetuximab
were introduced.
Pre-operative evaluation
Pre-operative staging included a physical examination, routine
blood tests and serum tumour marker assays [carcinoembryonic
antigen (CEA) and/or carbohydrate antigen (CA) 19-9],
colonoscopy, abdominal imaging by multislice computed tomog-
raphy (CT) and/or magnetic resonance imaging (MRI) of the liver
in the month before a laparotomy, and chest imaging by routine
radiography or CT. An 18F-FDG-PET scan was performed in
patients with more severe disease (e.g. multiple, synchronous,
bilobar CLMs).12 Disease resectability was determined in a multi-
disciplinary assessment by a team of surgeons and medical
oncologists. Unresectability was usually based on an insufficient
remnant liver volume.13 The type of hepatic resection was planned
pre-operatively on the basis of the CLMs’ characteristics in pre-
chemotherapy and pre-operative CT scans.
Liver resection
The surgical techniques and the various vascular control methods
used to reduce the intra-operative bleeding have been described
elsewhere.13,14 A hepatic parenchymal transection was performed
mostly with a compact ultrasonic surgical aspirator (CUSA;
Dissectron®; Integra LifeSciences, Plainsboro, NJ, USA) or, if not,
with a Kelly clamp crushing technique. The surgical goal was to
achieve complete resections with a tumour-free margin for all the
initially-identified tumour deposits (including missing metasta-
ses). If a tumour-free margin could not be obtained, the resection
was still performed when macroscopically-complete resection of
all metastases could be achieved. In accordance with the Interna-
tional Union Against Cancer guidelines,15 a R0 resection was
defined as any microscopically-complete resection with a margin
≥1 mm, and a R1 resection was defined as a complete macroscopic
resection with microscopic tumour invasion of the resection
margin (tumor free margin <1 mm). Three-month post-operative
morbidity and mortality were rated according to the Clavien–
Dindo classification.16 Complications were defined as severe when
they required repeat surgery or resulted in organ failure or patient
death (grades III to V16).
Follow-up
Administration of adjuvant chemotherapy was discussed in a
multidisciplinary staff meeting and by taking account of the
patient’s history and histopathological data. Patients were moni-
tored by the referring surgeon and/or oncologist, with a physical
examination, liver biochemistry assays, CEA/CA19-9 assays and
imaging of the abdomen every 3–6 months and a chest CT every
year. The goal of this regular follow-up was to offer curative treat-
ment in the event of recurrence where possible. A diagnosis of
recurrence was based on elevated CEA/CA19-9 levels and charac-
teristic imaging findings. The authors also analysed patterns of
recurrence and the corresponding treatments.
Statistical analysis
Continuous data were expressed as the mean ± standard deviation
and compared using the independent-sample t-test or Mann–
Whitney U-test, as appropriate. Categorical data were compared
using a chi-squared test or Fisher exact test, as appropriate. The
study’s primary endpoint was the survival time after a hepatec-
tomy. OS was defined as the time interval between the hepatec-
tomy and death or last follow-up. Disease-free survival (DFS) was
defined as the time interval between the hepatectomy and first
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post-operative recurrence or death. In order to consider the
pattern of recurrence and curability, the authors analysed
the progression-free survival (PFS) defined in that purpose as the
time interval between the hepatectomy and either the first recur-
rence that could not be treated curatively or death.8 The latter
parameter was investigated in order to assess putative relation-
ships between the pattern of recurrence, previous chemotherapy
and the likelihood of curative treatment. Survival rates were cal-
culated according to the Kaplan–Meier method and compared in
a log-rank test. To identify independent survival factors, factors
with P < 0.2 and their first interactions were included in a back-
ward step-by-step Cox proportional hazards model. Predictive
independent factors of a R1 resection were identified using a
logistic regression method. For assessing the effect of group (R0,
R1) on each outcome, we used a propensity score method17 to
adjust the analysis for observable differences between R1 and R0
patients. To compute the propensity scores, we used multivariate
logistic regression with group (R0 and R1) as the dependent vari-
able and independent variables selected from the multivariate
analysis, as significantly associated with one of the three out-
comes.18 Lastly, the effect of group on each outcome (OS, DFS and
PFS) was assessed using a Cox multivariate regression model with
group and propensity score as dependent variables. All analyses
were performed using SPSS software (version 17.0; SPSS Inc.,




Out of a total of 337 patients, 64 (18.9%) were excluded because of
a macroscopically incomplete (R2) resection (n = 6), concurrent
extrahepatic disease (n = 28), a history of other cancers (n = 14),
concomitant local treatment (n = 10) or because the final histo-
logical diagnosis did not correspond to CLMs (n = 6). Of the 273
eligible patients (81.1%), 59 patients (21.6%) had an R1 resection.
Comparison of demographics, treatment and potential predictive
variables of an R1 resection are shown in Table 1. Overall, patients
in the R1 group displayed a higher number of metastases (which
were often synchronous and bilaterally distributed) and/or a
larger metastasis size, reflecting worse tumour biology.
Recurrence patterns and treatments
After a mean follow-up period of 43 ± 29 months, recurrence had
occurred in 184 (67.4%) of the 273 patients (Table 2). Recurrence
at the resection margin was associated with another type of
intrahepatic recurrence in 4 of the 10 patients in the R1 group and
6 of the 12 patients in the R0 group (P = 0.485).When considering
only patients who received neoadjuvant chemotherapy, the differ-
ence in recurrence rates at the resection margin was no longer
significant between R0 (N = 10, 14.9%) and R1 groups (N = 5;
19.2%; P = 0.754).
The five-year OS, PFS and DFS rates for the population as a
whole were 51.3%, 46.1% and 28.4%, respectively. The 5-year
survival rates for the R1 group were markedly lower than those for
the R0 group (OS: 39.1% versus 54.2%, respectively, P = 0.010;
DFS: 15.2% versus 31.1%, P = 0.021; PFS: 33.1% versus 47.3%,
P = 0.033). With the more systematic use of chemotherapy since
2005 (chemotherapy rates of 88.6%, in association with targeted
therapies in 12.8% of patients, versus 79.6% before 2005; P =
0.044), a comparison of 141 R0 patients and 34 R1 patients
revealed a significant difference for OS (P = 0.024) and a trend
towards a significant difference for DFS (P = 0.081), whereas the
difference disappeared for PFS (i.e. time to the first non-curable
recurrence; P = 0.264). Univariate analysis and multivariate analy-
sis of factors associated with survival are shown in Table 3. To
counter bias as a result of differences in covariate distribution
between patients with R1 and R0 resections, a propensity score
analysis was performed using multivariable logistic regressions
with the group (R0/R1) considered as a dependent variable and 13
independent variables selected from the multivariate analysis
(Table 3). There were no statistically significant intergroup differ-
ences in terms of the OS rate [hazard ratio (HR): 1.3; 95% confi-
dence interval (CI): 0.79–2.1; P = 0.312], the DFS rate (HR: 1.3;
95% CI: 0.89–1.9; P = 0.171) or the PFS rate (HR: 1.3; 95% CI:
0.83–2; P = 0.240). Hence, in a multivariate analysis, margin status
was not a significant predictor of survival.
Discussion
In the current study population, a positive R1 surgical margin was
associated with a poor prognosis by univariate analysis. However,
a R1 resection was also associated with more advanced metastatic
disease and more complex resections. In a multivariate analysis,
the independent predictors of poor survival were related to
aggressive tumour biology such as severe metastatic burden (CLM
size, number and synchronicity), the N status of the colorectal
tumour and the presence of a rectal primary tumour, but not a R1
resection. Moreover, while the survival time to the first non-
curable recurrence was worse in the R1 group when considering
the overall population, this difference disappeared after 2005 with
the more systematic use of chemotherapy and the introduction of
targeted therapies, suggesting a chemotherapy-induced change in
pattern and curability of recurrences.
For several reasons the prognostic impact of margin status
seems questionable. First, in the current population, the outcome
in the R0 group did not appear to depend on the margin width, in
agreement with previous studies.2,19 Second, it can be assumed
that the parenchymal transection technique, i.e. ultrasonic dissec-
tor used in more than 75% of patients, has attenuated the impact
of a R1 resection. Indeed, the CUSA may crush and suck an
additional 2–4 mm of margin, transforming a R0 intra-operative
resection into a R1 pathological resection,2 resulting in an overes-
timation of the proportion of R1 resections.2 In a recent study, the
presence of a positive surgical resection margin did not influence
local and distant recurrence rates as long as a liver resection was
performed with a CUSA® by an experienced hepatobiliary
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Table 1 Clinicopathological features, operative procedures and post-operative outcome
R0 (n = 214) R1 (n = 59) P
Age 62.7 ± 10.2 62.7 ± 10.4 0.976
Primary tumour
Colonic origin 158 (73.8%) 46 (78%) 0.518
Rectal origin 56 (26.2%) 13 (22%)
CLM
Synchronous 115 (53.8%) 40 (67.8%) 0.054
Bilobar 36 (16.8%) 17 (28.8%) 0.039
CEA ≥10 UI/l 98 (45.8%) 37 (62.7%) 0.021
Peri-operative chemotherapy 181 (84.6%) 52 (88.1%) 0.494
Neoadjuvant chemotherapy 133 (62.1%) 43 (72.9%) 0.127
Number of cycles 8.5 ± 5.2 (2–32) 10.8 ± 6.2 (2–28) 0.010
LV5-FU2 5 (3.75%) 0 (0%)
FOLFOX or FOLFIRI 87 (65.4%) 28 (65.1%)
FOLFOX + FOLFIRI 16 (12%) 5 (11.6%)
FOLFOX or FOLFIRI + Biotherapy 21 (15.8%) 9 (20.9%)
FOLFOX + FOLFIRI + Biotherapy 4 (3%) 1 (2.3%)
Adjuvant chemotherapy 127 (59.3%) 31 (52.5%) 0.349
Number of cycles 7.4 ± 3.3 6.7 ± 2.8 0.192
LV5-FU2 12 (9.4%) 4 (12.9%)
FOLFOX or FOLFIRI 80 (63%) 17 (54.8%)
FOLFOX + FOLFIRI 10 (7.9%) 3 (0.95%)
FOLFOX or FOLFIRI + Biotherapy 24 (18.9%) 7 (22.6%)
FOLFOX + FOLFIRI + Biotherapy 1 (0.8%) 0 (0%)
Radiological response to chemotherapy 0.840
Response (%) 79 (59.4%) 25 (58.1%)
Stabilization (%) 45 (33.8%) 16 (37.2%)
Progression (%) 9 (6.8%) 2 (4.7%)
Type of hepatic resection
Anatomical or Wedge 168 (78.5%) 37 (62.7%) 0.013
Anatomical + Wedge 46 (21.5%) 22 (37.3%)
Major (≥3 segments) 131 (61.2%) 39 (66.1%) 0.493
Extended (≥5 segments) 24 (11.2%) 14 (23.7%) 0.014
Operative time (min) 283 (80–645) 323 (120–780) 0.030
Portal triad clamping 79 (36.9%) 26 (44.1%) 0.317
Total ischaemia (min) 20.1 ± 44.5 (0–110) 20.5 ± 23.7 (0–93) 0.962
Blood loss (ml) 470 ± 360 (10–2400) 597 ± 549 (10–3500) 0.110
Intra-operative transfusion 6 (2.8%) 5 (8.5%) 0.064
Transection CUSA 168 (78.5%) 44 (74.6%) 0.521
Number of CLM(s) 2.6 ± 2.5 3.3 ± 2.6 0.048
Cumulated diameter (cm) 4.7 ± 3.4 (1.3–20) 6.1 ± 3.3 (1.8–13.2) 0.016
Largest CLM size (cm) 3.5 ± 2.3 4.7 ± 3 0.070
At least one CLM ≥30 mm 117 (54.7%) 39 (66.1%) 0.116
Overall morbidity rate 80 (37.4%) 26 (44.1%) 0.351
Severe morbidity rate (grade III–V) 25 (11.7%) 11 (18.6%) 0.162
Mortality rate (Clavien V) 4 (1.9%) 2 (3.4%) 0.613
Data were expressed as the mean ± standard deviation; Results with borderline or statistical significance were indicated in bold; CLM, colorectal liver
metastasis; CEA, carcinoembryonic antigen.
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surgeon.20 Third, in the R1 group, a R1 resection was not a prog-
nostic factor after adjustment for metastatic severity, whereas
recurrence at the resection margin in the R1 group was associated
with another type of intra-hepatic recurrence in 40% of the
patients. In the current series, unlike the margin status, the
parameter of tumour biology, such as CLM size, number and
synchronicity were independent predictors of poor survival,
whether or not patients had received neoadjuvant chemotherapy.
Hence, the negative impact of R1 status on overall survival may be
related to the more aggressive tumour biology (making resection
of the tumour with negative surgical margins more difficult)
rather than the residual presence of microscopic tumour cells at
the surgical margin.21
The authors furthermore reviewed the largest series having
reported on survival rates after a CLM resection.1,2,5,6,8,22–34 Their
assessment first showed that the impact of a R1 resection on
survival has become progressively questionable over the last 10
years (Fig. 1). This contrasts with the more severe clinical and
histopathological characteristics35 and the increasing complexity
of a hepatic resection for CLMs.36,37 Increasingly efficient chemo-
therapy may have changed the long-term outcome after a R1
resection, especially in patients with advanced metastatic disease.
In three recent studies on neoadjuvant chemotherapy,24,33,34 there
were no differences in survival rates between R0 and R1 resection
groups, in particular in patients with optimal morphological or
histopathological responses.24 In contrast, the OS with R1 resec-
tion was still worse than with R0 for patients with suboptimal
responses to chemotherapy.24,33 This beneficial effect of
neoadjuvant chemotherapy could be related to the chemotherapy-
induced concentric shrinkage of the tumour;38 with chemo-
therapy, no micrometastases were found more than 4 mm beyond
the periphery of the tumour compared with 10 mm without
chemotherapy.27 Accordingly, the frequency of microscopic inva-
sion in patients having received pre-hepatectomy chemotherapy
was lower than in patients not having received chemotherapy,33,39
thus altering the prognostic impact of margin status. In the
current study, the recurrence rate at the surgical margin decreased
from 31.3% to 19.2% in the group R1 with the use of neoadjuvant
chemotherapy, and subsequently became comparable to that of
the R0 group.
Table 2 Pattern and treatment of recurrences
R0 (n = 214) R1 (n = 59) P
No recurrence 75 (35%) 14 (23.7%) 0.101
Recurrence 139 (65%) 45 (76.3%)
Site of recurrence(s)
Hepatic 45 (32.4%) 19 (42.2%)
Extra hepatic 50 (36.0%) 13 (28.9%) 0.465
Both 44 (31.6%) 13 (28.9%)
Time to recurrence (months) 27.8 ± 28.4 20.8 ± 27.5 0.029
Hepatic recurrence 89 (41.6%) 32 (54.2%) 0.083
Surgical margin 12 (13.4%) 10 (31.3%) 0.025
First recurrence curative treatment
(analysis by patient)
63 (45.3%) 16 (35.6%) 0.250
First hepatic recurrence curative treatment
(analysis by site)
Iterative hepatectomy 33 (37.1%) 8 (25%) 0.216
Including surgical margin recurrence 6 (6.7%) 2 (6.2%) 0.156
Radiofrequency 2 (2.2%) 4 (12.5%) 0.042
Including surgical margin recurrence 1 (8.3%) 2 (20%) 0.429
First extra-hepatic recurrence curative
treatment (analysis by site)
Surgery 30 (31.9%) 4 (15.4%) 0.098
Radiofrequency 1 (1.1%) 4 (15.4%) 0.008
Status at last follow up
Dead 82 (38.3%) 32 (54.2%) 0.028
Alive without recurrence 67 (31.3%) 11 (18.6%) 0.057
Alive without disease (including iterative
curative treatment of recurrence)
101 (47.2%) 21 (35.6%) 0.112
Overall survival (months) 44.6 ± 28.5 (1–133) 38.8 ± 30.3 (1–122) 0.050
Data were expressed as the mean ± standard deviation; Results with borderline or statistical significance were indicated in bold.
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Table 3 Univariate (UV) and multivariate (MV) analysis of 5-year overall (OS), disease-free (DFS) and progression-free (PFS) survivals












All patients 273 51 28 46
≥70 years 203 47 0.199 29 0.569 45 0.670
<70 years 70 52 27 45
ASA ≤2 234 52 0.424 26 0.085 45 0.828
ASA >2 39 42 42 41
Colon 204 55 0.118 0.054 32 0.008 NS 50 0.015 0.013
Rectum 69 40 1.5 [0.99–2.2] 18 33 1.6 [1.1–2.4]
CEA
<10 138 57 0.140 30 0.649 54 0.168
≥10 135 44 27 41
Chemo
Neoadjuvant 176 47 0.042 NS 39 0.001 NS 52 0.003 NS
No 97 57 22 40
Adjuvant 158 58 0.006 0.048 25 0.889 49 0.219
No 115 41 0.6 [0.4–0.9] 31 41
Peri-operative 233 51 0.662 25 0.026 NS 45 0.376
No 40 46 30 50
Hepatectomy
Major 170 55 0.209 26 0.183 42 0.246
Minor 103 48 30 50
≥5 seg 38 53 0.003 NS 15 0.003 NS 28 0.001 NS
<5 seg 235 35 30 47
Operative time 0.037 NS 0.160 0.064
Blood loss 0.004 NS 0.019 NS 0.002 NS
Transfusion 11 40 0.087 0 0.002 NS 15 0.001 NS
No 262 50 29 44
Complication 106 43 0.007 NS 24 0.442 35 0.082 NS
No 167 56 29 50
Unilobar 220 50 0.990 30 0.135 44 0.212
Bilobar 53 50 18 55
Stage T1 or T2 30 62 0.160 33 0.276 55 0.210
Stage T3 or T4 233 49 27 43
Stage
N0 128 63 0.008 0.008 39 0.005 NS 56 0.005 0.046
N+ 145 44 1.7 [1.1–2.7] 20 38 1.4 [1.1–2.1]
Stage
M0 118 49 0.160 35 0.002 NS 52 0.012 NS
M1 155 54 22 40
Time interval of CLM
occurrence
0.075 NS 0.001 0.005 0.004 0.038
0.6 [0.3–0.8] 0.6[0.6–0.9]
Number of CLM 0.001 0.003 0.001 0.006 0.001 0.018
1.1 [1.1–1.2] 1.1 [1.1–1.1] 1.1 [1.1–1.1]
Size of larger metastasis 0.001 0.001 0.001 0.006 0.001 0.003
1.1 [1.1–1.2] 1.1 [1.1–1.2] 1.1 [1.1–1.2]
Margin
R1 59 39 0.010 NS 15 0.025 NS 33 0.037 NS
R0 214 54 31 47
<10 mm 142 58 0.940 27 0.475 46 0.871
≥10 mm 72 49 35 48
<4 mm 94 46 0.715 24 0.460 47 0.813
≥4 mm 120 57 34 46
Differences in survival between the R0 and R1 groups were estimated using Cox’s proportional hazards model and expressed as hazard ratios (HR) with 95%
confidence (CI); Results with borderline or statistical significance were indicated in bold. NS, non significant (by multivariate analysis).
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Above all, two recent reports have suggested that peri-operative
chemotherapy is related to the pattern of recurrence, which in
turn may be related to long-term survival.40,41 Thus,Vigano et al.37
reported that the long-term outcome of a liver resection for CLMs
had improved over a 20-year period (even in patients with nega-
tive prognostic factors) and suggested that this improvement was
related to a reduction in recurrence, better chemotherapy of
recurrence and a higher resection rate. De Jong et al. also reported
that between 1982 and 2008, adjuvant chemotherapy favourably
influenced recurrence rates and patterns after a curative-intent
resection of CLMs.42 In contrast, in two recent studies that still
found a R1 resection to be independently associated with a poorer
survival, the authors did not comment on whether peri-operative
chemotherapy could have changed the pattern of recurrence and
thus the feasibility of curative treatment.23,24 In our population,
the use of adjuvant chemotherapy was independently associated
with an improved outcome. Moreover, in spite of the greater
disease severity in the R1 group, the difference in PFS (i.e. the
survival time to the first non-curable recurrence) between R0 and
R1 groups disappeared in patients operated on after 2005 (i.e.
once peri-operative chemotherapy and, in some cases, targeted
therapies had been administered more systematically). This time
period effect on survival suggests that more effective chemo-
therapy may be associated with a less ominous pattern of recur-
rence – suggesting the killing of a microscopic residual tumour left
behind at the time of surgery, on the resection margin or else-
where – offering a greater chance of curative treatment.
In conclusion, R1 margin status may be a surrogate indicator of
advanced and/or more extensive disease rather than an independ-
ent predictor of survival. In today’s patients with severe metastatic
disease, R1 status’ lack of prognostic impact reflects improve-
ments in chemotherapy. Neoadjuvant chemotherapy may help to
narrow surgical margins, whereas adjuvant chemotherapy may
cure residual micrometastatic disease; both of these approaches
should increase the likelihood of curative repeat resection in the
event of recurrence. Taken as a whole, these data suggest that
peri-operative chemotherapy should not be questioned in patients
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Figure 1 Literature review on the main studies specifically dedicated to margin status for colorectal liver metastase (CLM) for the past 10
years and comparing R0 to R1 resections. Circles represent the P-values of the univariate analysis (white circle) and/or multivariate analysis
(black circle). The dotted line represents a significance threshold 0.05
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